Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.

Medical oncology (Northwood, London, England) - 1 Jan 2014

Tao Leilei, Huang Guichun, Shi Shujing, Chen Longbang

Abstract excerpt

Cytokine-induced killer cells (CIK cells) are a heterogeneous population of cells generated from peripheral blood mononuclear cells, which share phenotypic and functional properties with both natural killer and T cells. CIK cells therapy, as an adoptive immunotherapy with strong antitumor activity in vitro, represents a promising approach for the treatment of a broad array of malignant tumors. However, clinical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Bevacizumab

Share to Hypoxia

Share to Immunotherapy, Adoptive

Share to Leukocytes, Mononuclear

Share to Mice, Inbred BALB C

Share to Xenograft Model Antitumor Assays

Source

Identifiers

PMID: 24271420
DOI: 10.1007/s12032-013-0777-3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Bevacizumab improves the antitumor efficacy of adoptive cytokine-induced killer cells therapy in non-small cell lung cancer models.PMID 24271420Read ↗

Natural killer cell‑based immunotherapy for lung cancer: Challenges and perspectives (Review)Semantic proximity Read ↗

Cellular immunotherapy as maintenance therapy prolongs the survival of the patients with small cell lung cancer.Semantic proximity Read ↗

The effects of cytokine-induced killer cells for the treatment of patients with solid tumors: a clinical retrospective study.Semantic proximity Read ↗

The phenotype of ex vivo generated cytokine-induced killer cells is associated with overall survival in patients with cancer.Semantic proximity Read ↗

Genome-wide DNA methylation signature predict clinical benefit of bevacizumab in non-small cell lung cancerSemantic proximity Read ↗

A Novel Combination of Bevacizumab and Pembrolizumab Stimulates Tumour Immunity Through Vascular Normalisation in Humanised Mouse ModelSemantic proximity Read ↗

Effective activity of cytokine-induced killer cells against autologous metastatic melanoma including cells with stemness features.Semantic proximity Read ↗

Bevacizumab Reduces S100A9-Positive MDSCs Linked to Intracranial Control in Patients with EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Docetaxel enhances CD3+ CD56+ cytokine-induced killer cells-mediated killing through inducing tumor cells phenotype modulation.Semantic proximity Read ↗

Autologous CIK cell immunotherapy in patients with renal cell carcinoma after radical nephrectomy.Semantic proximity Read ↗

Synergistic effects of cannabidiol and cytokine-induced killer cells via the modulation of TRPV2 channel and intracellular p-ERK 1/2 expression on non-small cell lung cancer cellsSemantic proximity Read ↗

PDGFRβ-antagonistic affibody mediated tumor-targeted TNFα for enhanced radiotherapy in lung cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.